Sagittarius Life Science
Sagittarius Life Science Corp engages in the research, development, and sale of Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.
Sagittarius Life Science (3205) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.000x
Based on the latest financial reports, Sagittarius Life Science (3205) has a cash flow conversion efficiency ratio of 0.000x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$125.00K) by net assets (NT$1.06 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sagittarius Life Science - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Sagittarius Life Science's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sagittarius Life Science Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sagittarius Life Science ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiin Ming Industry Co Ltd
TWO:3230
|
0.026x |
|
Digital China Holdings Limited
TW:910861
|
-1.299x |
|
CIG WIRELESS
F:6CW
|
-0.590x |
|
S.Y.PANEL Co Ltd
KQ:109610
|
-0.087x |
|
OUTSURANCE GROUP LTD
JSE:OUT
|
0.349x |
|
Tu Liem Urban Development JSC
VN:NTL
|
-0.024x |
|
Prolific Technology
TWO:6233
|
-0.006x |
|
Sumiseki HoldingsInc.
PINK:SMSKF
|
N/A |
Annual Cash Flow Conversion Efficiency for Sagittarius Life Science (2015–2024)
The table below shows the annual cash flow conversion efficiency of Sagittarius Life Science from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$419.76 Million | NT$-44.48 Million | -0.106x | +19.51% |
| 2023-12-31 | NT$526.90 Million | NT$-69.37 Million | -0.132x | -13.36% |
| 2022-12-31 | NT$455.42 Million | NT$-52.89 Million | -0.116x | -111.62% |
| 2021-12-31 | NT$531.71 Million | NT$-29.18 Million | -0.055x | +48.12% |
| 2020-12-31 | NT$588.38 Million | NT$-62.24 Million | -0.106x | +31.72% |
| 2019-12-31 | NT$674.50 Million | NT$-104.50 Million | -0.155x | -113.51% |
| 2018-12-31 | NT$797.37 Million | NT$-57.86 Million | -0.073x | -200.52% |
| 2017-12-31 | NT$965.47 Million | NT$-23.31 Million | -0.024x | -108.12% |
| 2016-12-31 | NT$1.21 Billion | NT$360.37 Million | 0.297x | -10.68% |
| 2015-12-31 | NT$714.71 Million | NT$237.94 Million | 0.333x | -- |